

DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

June 2017

Remember: Clicking the **coloured links** will take you to more information!



Don't forget: DRIVE-AB is on **Twitter!** Don't miss out - follow us at **@DRIVE_AB**.

Online Registration Now Open: "Revitalizing the Antibiotic Pipeline"



The **DRIVE-AB Final Conference, "Revitalizing the Antibiotic Pipeline"**, will be held on **5-6 of September 2017 in Brussels, Belgium at the Crowne Plaza**. The conference will bring together high-level policy makers, regulatory and public health experts, economists and representatives of pharmaceutical companies, the medical community and civil society to discuss DRIVE-AB results and recommendations and suggest solutions for their implementation around the globe. Some confirmed faculty members include representatives from the World Health Organization, the European Commission, the Biomedical Advanced Research and Development Authority, the Drugs for Neglected Diseases initiative, and the EU Joint Programming Initiative for AMR. 24 posters on DRIVE-AB research and results will be showcased at the conference.

Spaces are filling up fast - if you are interested in attending the conference, please register your interest with Victoria Wells (VWells@BSAC.org.uk) now.

DRIVE-AB Regrets that ReAct is No Longer a Consortium Partner

DRIVE-AB regrets that **ReAct** has decided to leave the DRIVE-AB partnership. We believe that ReAct has contributed positively to the conversations and development of DRIVE-AB's research. With ReAct leaving, we lose an important voice within the project to represent civil society. **Please [click here to read the full statement](#).**

DRIVE-AB Recommends Actions for G20 Leaders

A commentary article identifying recommended actions for G20 leaders and outlining some of our preliminary results has been accepted for publication in *The Lancet Infectious Diseases* and will be available on 6 July; check our **[website](#)** for updates.

Survey on Global Incidence of AMR Now Live

Work Package 1B has completed a survey on the global incidence of four drug-resistant organisms, which will help to inform DRIVE-AB's final recommendations. The survey has been promoted in the WHO Save Lives newsletter and is available online: **[click here to find out more](#).**



DRIVE-AB Represented at INFORMS Healthcare Conference 2017

Consortium partner Abby Colson will speak on the topic of DRIVE-AB **Work Package 1C** expert elicitation work at the **conference on "Optimizing Operations and Outcomes"** in Rotterdam on 26-28 July, 2017.



DRIVE-AB Partner Céline Pulcini Receives Young Investigator Award

DRIVE-AB congratulates Work Package 1A partner Céline Pulcini on receiving the prestigious **European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Young Investigator Award**.

What Have We Been Up To?



DRIVE-AB Symposium Featured at ICPIC 2017

The **International Conference on Prevention and Infection Control (ICPIC)** was held in Geneva, Switzerland on 20 - 23 June 2017 and featured a **DRIVE-AB symposium**. The symposium, "Responsible antibiotic use and new developments", was held on Friday 23 June and was well attended. **[Click here to see the conference website for more details](#).**



Workshop: Sustainable use policies within a new multi-sectoral framework for antibiotics

DRIVE-AB, collaborating with **CARB-X** and the **Brocher Foundation**, hosted a small, invitation-only workshop with some key stakeholders on sustainable use policies within a new multi-sectoral framework for antibiotics. The workshop was held in Geneva, Switzerland on 18-19 May 2017. **[Click here to read more](#).**



DRIVE-AB Showcased at ECCMID and European Networking Corner

DRIVE-AB was well represented at this year's **ECCMID**, which was held from 22 - 25 April 2017 in Vienna, Austria. The consortium presented a total of six abstracts and showcased a poster at the European Networking Corner. [Click here to view the poster](#) and [click here to read more](#).

Recent DRIVE-AB Outputs

- [Poster presented at the ECCMID European Networking Corner](#)
- Commentary in [The Lancet Infectious Diseases](#): "To the G20 - Next steps for incentivizing antibacterial R&D"
- Article in *Infectious Diseases Reports*: ["Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development"](#)
- Abstracts presented at the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID):
 1. "Views and experiences of currently or recently hospitalized patients in four European countries with regard to barriers and facilitators to responsible antibiotic use: a qualitative descriptive study"
 2. "Barriers and facilitators of responsible systemic antibiotic use from the patient's perspective: a systematic review"
 3. "Towards a global definition of responsible antibiotic use. Results of the DRIVE-AB project"
 4. "The Impact of Antibiotic Use on Transmission Dynamics of Antibiotic-Resistant Bacteria in the Hospital Setting"
 5. "Identification and modeling of antibiotic-resistant bacteria worldwide"
 6. "Estimating the current number of Third-Generation Cephalosporin-resistant E. coli and K. pneumoniae infections worldwide"

[To view all DRIVE-AB outputs to date, please see our website.](#)

Project updates by work package

[Responsible use of antibiotics, new and old](#)

In addition to presenting three abstracts as posters at the 2017 European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), the team is entering the final stages of preparation of a series of systematic reviews and original articles which will be presented for publication in a supplement of the *Journal of Antimicrobial Chemotherapy* at the end of 2017. For more detailed information on the group's progress or to view their most recent articles and abstracts, please see WP1A's [webpage](#).

[Setting, communicating and revising public health priorities](#)

In addition to presenting three abstracts at ECCMID 2017, the group is drafting three further manuscripts on the incidence of antibiotic-resistant E. coli and Klebsiella, estimating future levels of antibiotic resistance in communities and hospitals in selected European countries, and the impact of immigrants and refugees on the global spread of antibiotic-resistant bacteria. They are also making headway in the development of a website to host maps with projected numbers and rates of infections of select multidrug-resistant organisms. The team recently released a survey on current

incidence of carbapenem-resistant Pseudomonas, VRE. For more detailed information on the group's progress or to access the survey, please see WP1B's [stakeholder engagement webpage](#).

[Antibiotic Evaluation](#)

The team has completed stakeholder interviews and expert elicitation to estimate the burden of antimicrobial resistance, which will inform the finalization of the recommended models developed by Work Package 2. For more detailed information on the group's progress or to register your interest in attending the stakeholder meeting, please see WP1C's [stakeholder engagement webpage](#).

[Creation and testing of new economic models](#)

In addition to publishing a commentary in the Lancet Infectious Diseases, the team is working to finalise their shortlist of incentives and reward models to stimulate investment in antibiotic R&D, and a simulator on antibiotic innovation has been built, which will be used to test some of the group's shortlisted models. The team is also designing sustainable use and equitable availability policies and has begun drafting the final report and recommendations for implementation. For more detailed information on the group's progress, please see WP2's [stakeholder engagement webpage](#).

[Project management and governance](#)

Along with ongoing project monitoring and management activities, the team has addressed scientific questions from the IMI and continues to aid in the development of the final report and in the organization of the final DRIVE-AB Conference, which will be held on **5-6 September 2017 at the Crowne Plaza in Brussels, Belgium**. For more detailed information on the group's progress, please see WP3A's [webpage](#).

[Stakeholder platform and external communication](#)

In addition to managing internal and external communications through oversight of the DRIVE-AB communications strategy, website and social media, the team continues to coordinate the engagement of existing and novel stakeholders. They are also busy working with WP3A to organize the final DRIVE-AB Conference. For more detailed information on the group's progress, please see WP3B's [webpage](#).

[Edit your subscription](#) | [Unsubscribe](#)